GREENWICH LIFESCIENCES Planned GP2 Phase III Clinical Trial A Breakthrough Targeted Immunotherapy to Prevent Breast Cancer Recurrences NASDAQ: GLSI Snehal Patel, CEO David McWilliams, Chairman © 2020 GLSI Image: T-cells targeting cancer cell Safe Harbor Statement This document is the property of Greenwich LifeSciences, Inc., (the "Company" or "Greenwich LifeSciences"). This document is non-directive in nature (contains no recommendations regarding financial actions related to the Company). This document is ...